



VIJAYA[®]
DIAGNOSTIC
CENTRE

May 29, 2023

To,
Listing Department
National Stock Exchange Of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
NSE Symbol. VIJAYA

To,
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers,
25th floor, Dalal Street,
Mumbai - 400 001
BSE Scrip Code. 543350

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 29th May 2023.

Ref: Regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations" or "SEBI (LODR) Reg., 2015") as amended from time to time.

We hereby inform you that, the Board of Directors in their meeting held today i.e., on **Monday, May 29, 2023**, has inter-alia considered and approved:

1. The Audited Financial Results of the Company for the quarter and year ended March 31, 2023. In terms of the above, we are enclosing herewith the following:
 - a. Audited Consolidated Financial Results of the Company and its subsidiaries for the quarter and year ended March 31, 2023, as per Indian Accounting Standards ("Ind AS").
 - b. Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2023, as per Indian Accounting Standards ("Ind AS").

Pursuant to Regulation 33 of the Listing Regulations, the Audit Reports of the Statutory Auditors on the financial results as mentioned at point nos. a & b are also enclosed.

We would like to confirm that the Statutory Auditors of the Company have issued Audit Reports with '**Unmodified Opinion**' on the Audited Financial Results of the Company (Standalone and Consolidated) for the year ended March 31, 2023.

2. Recommendation of dividend of Re. 1/- per equity share (@100% on a face value of Re. 1/- per share) for the year ended March 31, 2023, subject to approval of the Shareholders at the forthcoming Annual General Meeting ("AGM") of the Company. The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course.



3. The appointment of **Ms. Sura Suprita Reddy** (DIN: 00263618) as the Additional Director in the category of Managing Director & Chief Executive Officer (MD & CEO) of the company for a period of Five (5) consecutive years with effect from 01st July 2023 to 30th June 2028, on the recommendation of the Nomination and Remuneration Committee, subject to the approval of shareholders at the ensuing Annual General Meeting.
4. The re-appointment of **M/s. B S R and Co.**, Chartered Accountants (Firm Registration No. 128510W) as the Statutory Auditors of the Company for a period of five (5) consecutive years commencing from the conclusion of 21st Annual General Meeting till the conclusion of the 26th Annual General Meeting of the Company, subject to the approval of the shareholders at the ensuing 21st Annual General Meeting of the Company.
5. The re-appointment of **M/s. Santhosh & Associates**, Cost Accountants (Firm Registration No. 003955) as the Cost Auditors of the Company for the Financial Year 2023-24.

The other details as required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09th September 2015, for the above point no's. 3 to 5, is enclosed herewith as **Annexure-A.**

Further, the Nomination and Remuneration Committee of the Board of Directors of the Company, at its meeting held on today i.e. Monday 29th May 2023, has granted 2,51,291 (Two Lakh Fifty One Thousand Two Hundred and Ninety One only) Employee Stock Options (ESOPs) convertible into 2,51,291 equity shares of face value of Re. 1/- each under the "VDCL Employee Stock Option Plan 2018".

The grant of the above stock options is in line with the provisions of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 as amended from time to time. The Disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed herewith as **Annexure-B.**

The Board Meeting commenced at 12:30 p.m. and concluded at 06:00 p.m.

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

Encl.: As above



Annexure A

Details Pertaining to Appointment/Re-Appointment

Particulars	Ms. Sura Suprita Reddy	M/s. B S R and Co., Chartered Accountants	M/s. Santhosh & Associates, Cost Accountants
Reason for Change	Appointment	Re-appointment	Re-appointment
Date of Appointment/Re-Appointment/Cessation	01 st July 2023	From the conclusion of 21 st AGM till the conclusion of the 26 th AGM of the Company, subject to the approval of the shareholders at the ensuing 21 st AGM of the Company	29 th May 2023
Term of Appointment	Appointed for a period of Five (5) consecutive years from 01 st July 2023 till 30 th June 2028 subject to the approval of shareholders at the ensuing 21 st AGM	Re-appointed for a period of five (5) consecutive years	For the Financial Year 2023-24
Brief Profile	<p>Ms. Sura Suprita Reddy is the Chief Executive Officer of Vijaya Diagnostic Centre Limited. She has been associated with the Company since 2003. Since then, she has been heading the overall strategy, clinical excellence, operations, and expansion of the company in its home markets and beyond. With return metrics and best in class profitability, Ms. Reddy has been driving its growth giving the centre the lead in the market.</p> <p>Ms. Reddy is known for her entrepreneurial skills and conscientiousness. She took a keen interest in the business at a very early age. After studying commerce from Osmania University, she was able to use her skills</p>	<p>M/s. B S R and Co ('the firm') was constituted on 01 September 2007 as a partnership firm having firm registration no. as 128510W. The registered office of the firm is at 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai-400063.</p> <p>B S R and Co is a member entity of B S R & Affiliates, a network registered with the Institute of Chartered Accountants of India.</p> <p>B S R and Co is registered in Mumbai, Gurgaon, Bangalore and Hyderabad.</p>	<p>M/s. Santhosh & Associates have extensive experience in the fields of Cost Audits, Cost Compliances, Cost Record maintenance, Cost Consultancy services Corporate Law, Secretarial Compliances, Tax Matter, audit and accountancy covering a wide range of sub activities related to the profession.</p>



	<p>to help the company grow. Because of her, in less than 2 decades, the company was able to earn revenue of over INR 4500 million from INR 70 million. Her business acumen and deep understanding of the business has helped the company remain competitive and offer the latest technology in diagnostics at an affordable price.</p> <p>Ms. Reddy also believes in helping the needy and spares adequate time in her busy schedule for the welfare of the society. Her contribution towards education and healthcare in rural area were remarkable.</p>	<p>B S R and Co together with its member firms has around 4000+ staff and 200+ Partners.</p> <p>B S R member firms audits various companies listed on stock exchanges in India including companies in the diagnostics and healthcare sector.</p>	
Disclosure of Relationships between directors	<p>Ms. Sura Suprita Reddy, is a part of Promoter & Promoter Group of the company. She's the daughter of Dr. Sura Surendranath Reddy, Executive Chairman and Ms. Sura Geeta Reddy, Director, of the company. Further, she is also the sister of Mr. Sunil Chandra K, Executive Director, of the company.</p>	None	None
Declaration	<p>We hereby affirm that Ms. Sura Suprita Reddy is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.</p>	Not applicable	Not applicable



Annexure-B

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III

S. No.	Particulars	Details
1.	Brief details of options granted	2,51,291 (Two Lakh Fifty One Thousand Two Hundred and Ninety One only) Employee Stock Options (ESOPs) granted to the eligible employees of the company under “VDCL Employee Stock Option Plan 2018”
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2014 (if applicable)	Yes
3.	Total number of shares covered by these options	2,51,291 (Two Lakh Fifty One Thousand Two Hundred and Ninety One only) of face value of Re. 1/- each of the Company
4.	Pricing formula (Exercise Price)	The said ESOPs are being granted at Rs. 318/- (Rupees Three Hundred and Eighteen Only) per option. The said price is the average closing price of the shares during the three (3) months preceding the month of the grant date and after providing a discount of 20%.
5.	Options vested	Not applicable <i>Options will start vesting after a period of one (1) year from the date of grant.</i>
6.	Time within which option may be exercised	Options shall be exercised from the date of the respective vesting of options and shall be exercised within the ‘ <u>exercise period.</u> ’ <i>Exercise Period – means the period of Ten (10) years from the grant date.</i>
7.	Options exercised	Not Applicable
8.	Money realized by exercise of options	Not Applicable
9.	The total number of shares arising as a result of exercise of option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation of terms of options	Not Applicable
12.	Brief details of significant terms	VDCL Employee Stock Option Plan 2018 (“the plan”) is administered and implemented by the Nomination and Remuneration Committee of the Board of Directors in accordance with the plan.



The grant of options is based on the eligibility criteria as mentioned in the plan.

Other significant terms of the Plan are as follows:

- Acceptance of the Grant: on or before the "Closing Date" which shall not be more than Thirty (30) days from the date of issuance of Grant Letter.
- Minimum Vesting Period: One (1) Year From the date of Grant of ESOPs.
- Vesting Schedule: under the plan, the company has formulated a total of six (6) different category of ESOP schemes for the purposes of vesting and exercise of ESOPs for different category of employees. The ESOPs shall vest as per the vesting schedule in the manner as defined under the respective scheme.

The current grant of ESOPs is being made under the ESOP scheme-5 & scheme-6. For details pertaining to the vesting schedule of the aforesaid schemes, please refer the **note**.

- The Shares arising out of Exercise of Vested Options shall not be Locked-in.



Note: -

S. No.	Particulars	Scheme 5	Scheme 6
1.	Nature of Options	Time based options	Combination of Time based and Performance based options.
2.	Category of employees to be considered	Employees of Support functions (Finance, Accounts, IT, Strategy, Operations, etc.)	Senior Management, Sales & Marketing teams
3.	Vesting Schedule	Year 1 - 25% Year 2 - 25% Year 3 - 50%	Performance Options* (70%) Year 1 - 25% Year 2 - 25% Year 3 - 25% Year 4 - 25% Time Options (30%) Year 1 - 0% Year 2 - 25% Year 3 - 50% Year 4 - 25%

*Performance Options will vest based on the individual performance rating of the employee as assigned during the appraisal process for a particular year, in the manner given below:

Individual performance rating	% of the Performance Options that will vest
Rating 5	100% of the Performance Options will vest
Rating 4	80% of the Performance Options will vest 20% of the Performance Options will lapse
Rating 3	70% of the Performance Options will vest 30% of the Performance Options will lapse

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing,
6th Floor, Unit-3, Sy No. 83/1, Plot No. 02,
Raidurg, Hyderabad – 500 081 – India
Tel: +91 407 182 2000
Fax: +91 407 182 2399

Independent Auditor's Report

To the Board of Directors of Vijaya Diagnostic Centre Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as the "Company") for the year ended 31 March 2023, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33

Registered Office:

B S R & Associates (a partnership firm with Registration No. BA69226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-8182) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited

of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited

underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

- a. The standalone annual financial results include the results for the quarter ended 31 March 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT
KUMAR
BAJAJ

Digitally signed by
AMIT KUMAR BAJAJ
Date: 2023.05.29
17:31:04 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

29 May 2023

Membership No.: 218685

UDIN:23218685BGXHIQ4375



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2023

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2023	31 December 2022	31 March 2022	31 March 2023	31 March 2022
		Audited (Refer Note 4)	Unaudited	Audited (Refer Note 4)	Audited	Audited
1	Income					
	% Obs bkr b'ad j nbo ql kp	1,500 / 6	1,641 -	1,041 - 2	11,624 60	12,546 60
	% Lq bo bk l j b	120 - 1	104 / - 1	100 . 3	1,24 00	1,06 4.
	Total income	12,286.33	11,469.44	11,705.21	46,415.26	46,379.64
2	Expenses					
	% l p' l e j q'of ip l kpr j ba	2 / 0 - -	101 . - /	141 4 . /	2,425 4.	3,562 / .
	% Bj nil vbb b'k' b'p b' m' k' p' b	6- 0 52	6/ 1 44	54- 63	4,316 6-	3,534 33
	% Ck k b l p p	242 5-	22/ 46	10- . 4	1,54 3.	3/ 2 23
	% Abnub f ql k ka j l c'p' ql k b' m' k' p' b' % b' c' b' l q' 2	0. 64	1 / - 05	2. 1 13	3,06 10	2,032
	% Lq bo bunik p' b' p	0264 / 3	01 3/ 14	0- 16 31	032/ 0.	1,006 15
	Total expenses	8,731.88	9,301.43	8,612.35	35,287.96	31,941.56
3	Profit before tax [1-2]	3,554.45	2,168.01	3,092.86	11,127.30	14,438.08
4	Tax expense					
	% r' o' b' k' q' u	45 / - -	251 - -	5. 1 3.	1,420 - -	1,055 - 3.
	% A' b' c' b' a' q' u	5 - - 2	90/ 00	35 4 .	2- 6.	20 - -
	Total tax expense	862.05	551.67	745.90	2,803.91	3,627.61
5	Profit for the period/year [3 - 4]	2,692.40	1,616.34	2,346.96	8,323.39	10,810.47
6	Other comprehensive income					
	Items that will not be reclassified to profit or loss					
	% Obj b pr obj bk' q' l c' a' b' k' b' a' b' k' b' d' q' l i' f' l' q' l' k' p' q' b	3 43	3 06	00 . 5	1,2 6.	1,2 20
	% Rk l j b q' u' o' b' i' q' d' q' l' s' b' k' p' j	4 -	3 .	2 02	3 2/	3 10
	Other comprehensive income for the period/year (net of tax)	5.06	4.78	24.83	19.39	19.10
7	Total comprehensive income for the period/year [5 + 6]	2,697.46	1,621.12	2,371.79	8,342.78	10,829.57
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6)					
9	Other equity				201 55 - 6	126 45 05
10	Earnings per equity share (face value of Re. 1 each fully paid up)					
	(Refer Note 6)	% l q' kkr i' f' b' a	% l q' kkr i' f' b' a	% l q' kkr i' f' b' a	% kkr i' f' b' a	% kkr i' f' b' a
	□ p' % k' O' p	17 31	25	17 / 0	5 . 3	1- 3-
	□ A' f' i' r' q' u' % k' O' p	17 30	25	17 / 6	5 . /	1- 21

Notes:

1. eb lsb pq ka il kb dk k f i obpr i q l e s g v Af dkl p f b k p b l f j f i p a % q b l j m kv e s b b k n o m o b a f k l c a k b t f e q b o b l d k f i l k k a j b p r o b j b k q n e k f i n b p i f a l t k f k a f k l r k q k d P q k a p % a k a P n o p e f b a r k a b o P b q l k . 0 0 l e q b l j m k f b p q / - . 0 % q b q o b a t f e q b o b i s k q c r i b p e b o r k a b o l q b o l r k q k d m e k f i n b p d b k b o i i v b n p a f k R a f k a f k e q o j p l e O b d r i q l k 0 0 1 e P b r o f e p b k a B u e k d b l c a l e R a f % f p q k d L i f d q l k p k a A f i l p r o b O b n r f o j b k p O b d r i q l k p l - . 2) p j b k a b a

2. eb lsb pq ka il kb dk k f i obpr i q t b o b o s f b t b a v q b r a q l l j j f i p b k a n m l s t a v q b l c a l e A f o b q o p k f e b o b n r q s b j b b k d p e b i a l k / 6 J v / - / 0 eb lsb obpr i q e s b b k p r g b q a i q r a q l v q b b p q q d o v r a q l o p l e q b l j m kv o e b p q q d o v r a q l o p e s b b u n o b p p a k r k j l a f e b a r a q l m k f l k l k e q b p o b p r i q p

3. eb l j m kv e p l k b o b n o l q i b p b j b k q % f w A f d k l p f p b s f b p p n o b q e b o b n r f o j b k p l e R a q P - 5) L n b o q d k P b d j b k p

4. eb pq ka il kb d r o b p d o q e b n r c p o b k a b a 0 . J o e / - / 0 k a 0 . J o e / - / - o b q b i k f d k d o b p b q b k q b r a f e b a p q ka il kb d r o b p f k o b n r q l e q b o r i i d k k f i v b o k a q b m r i f e b a r k r a f e a v b o q i a q p j q ka il kb d r o b p r m q l e q b a q l e q f a i n r o p o l e q b o b n r q s b d k k f i v b o p

5. eb l j m kv e p i e o d b a a b n o b f q l k l k M l n b o y) M k q l k a B n r f i n j b k q p h a l k T o f e k A l t k S i r b % T A S q b q l a a d j q . q n e f i / - / q d . 0 . A b b j b o l - / - T f e b a b q o d j q . k r o w / - / 0 q b l j m kv e p i e k d b a f i p j b q l a l e a b n o b f q l k a d j T A S q l P l J % B p f e q l f k b j b q l a q p h a r m k e q b q e k f i p p b p j b k q l e b u n b q a m q h k l e l k p r j m q l k l e q b o r q o b b l k l j f i b k d i p b j l a f a i k e q b p p b o p l c a l k d i v) q e b a b n o b f q l k b u n k p b f i p i l t b o k a n e d q b d o b q u f i p e f e b o v O p : 5 6 6 - 5 i h e p d o q b n r o p o k a v b o b k a b a 0 . J o e / - / 0 e b o b f p k l f j m q l k l r k q l e p e e k d b q q e b a b n o b f q l k m l s f a b a f k e q b o b p r i q d o q b n r o p o k a k f k b j l k e p n b o l a b k a b a 0 . A b b j b o l - / -

6. A r o k d q e b n r o p o k a v b o b k a b a 0 . J o e / - / 0 q b l j m kv e p f i p r b a q 6 . 0 k a q - 2) 1 6 b n r f y p e o b p l e e b i s i r b l e O b q b e o b n r q s b i v l k b u b o f i b l e b j m l v b b p d h l m q l k p

7. eb l c a l e A f o b q o p q f i p j b b k d e b i a l k / 6 J v / - / 0 e p n o l m p a k a o b l j j b k a b a i s f a b k a l e O b q , i n b o b n r f y p e o b l e O b q , l b e f b) - - " d e q b e k k f i v b o l - / - / 0) p r g b q d q e b m l s i l e q b j b j b o p q e b b k p r f k d k k r i d b k b o i j b b q k d

8. eb obpr i q l e q b l j m kv o b s s i f e d o f k b p l o p q t t t s g v a f d k l p f l j) t t t k p o k a f l j q k a i t t t p h k a f l j

9. l o o p n l k a f k d n o s f l r p n b o l a e d r o b p e s b b k o b d o l r n b a o b i p p f e a i e b o s b o k b b p o v

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANATH
REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2023.05.29 17:07:16
+05'30'

Dr. S. Surendranath Reddy
Bub r q s b e f o j k
AF 7- - - 5266

Standalone Balance Sheet		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	As at	As at
		31 March 2023	31 March 2022
		Audited	Audited
	ASSETS		
I	Non-current assets		
	% [Ml nboq] ni kq ka bnr finj bkq	5,24 - 2	5,1 - 4
	% [nq i i l ch nk nol dobp	4 - 3	0 - -
	% [Ofleq l c r pb] ppbp	/ y 00 6/	34,2 / 2
	% [Ks bpj] bkq ml nboq bp	- - 50	- - 24
	% [Lq bofkq kdf ib] ppbp	. 6 / 0	02 - 0
	% [Kq kdf ib] ppbp ka ba bs bil nj bkq	30 - 3	3 51
	% [Cfk k f i] ppbp		
	% [Ks bpj] bkq	1 54 02	1 54 02
	% [l k p	242 - -	242 - -
	% [Lq boefk k f i] ppbp	51 1 15	41 - 53
	% [Abcoba] q u ppbp %bkq	436 22	5 / 3 65
	% [l k r oobkq q u] ppbp %bkq	0 40	0 40
	% [Lq bo] kl k r oobkq ppbp	53, 2	/ y / 4 5
	Total non-current assets	58,026.32	44,650.23
II	Current assets		
	% [Ks bkq] ofbp	6 / 31	1 - 6 66
	% [Cfk k f i] ppbp		
	% [Ks bpj] bkq	0 566 0/	2 / 0 22
	% [o a b ob bs ibp	552 . 0	61 5 34
	% [pe ka] pe bnr fs ibkq	/ 0 / 5 64	- 06 - /
	% [kh] i k bpl q bo q k % [l s b	5 5 . 0 26	4 233 1 5
	% [l k p		- 1 64
	% [Lq boefk k f i] ppbp	026 33	202 . /
	% [Lq bo] r oobkq ppbp	2 - - 32	1 - 2 . 1
	Total current assets	26,979.96	26,432.94
	TOTAL ASSETS (I + II)	85,006.28	71,083.17
	EQUITY AND LIABILITIES		
I	Equity		
	% [Bnr fq] pe ob nq i	- / - 4	- . 6 33
	% [Lq bo] bnr fq	20 / 55 - 6	1 2 645 05
	Total equity	54,508.80	46,998.04
II	Liabilities		
II	Non-current liabilities		
	% [Cfk k f i] if fifq bp		
	% [b pb] if fifq bp	/ 0 0 - -	4 - / 2 64
	% [Ml s] fl k p	351 02	4, / - 1
	% [Lq bo] kl k r oobkq if fifq bp	3 - 4	1, 32
	Total non-current liabilities	24,033.43	17,749.66
III	Current liabilities		
	% [Cfk k f i] if fifq bp		
	% [b pb] if fifq bp	2 / 56	23 50
	% [o a b m v ibp		
	% [l q i l r q q ka fkd ar bpl c j f d [bkq] onuf bp] ka [pj ii bkq] onuf bp] ka	2, / 3	2 26
	% [l q i l r q q ka fkd ar bpl c] oba f d opl q bo q k j f d [bkq] onuf bp] ka [pj ii bkq] onuf bp]	334 65	- / 0 34
	% [Lq boefk k f i] if fifq bp	036 4/	2, 05
	% [Ml s] fl k p	002 16	21 32
	% [r oobkq q u] if fifq bp %bkq	/ 02 / .	56 33
	% [Lq bo] r oobkq if fifq bp	02, 2-	01 0 36
	Total current liabilities	6,464.05	6,335.47
	Total liabilities (II + III)	30,497.48	24,085.13
	TOTAL EQUITY AND LIABILITIES (I + II + III)	85,006.28	71,083.17

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANA
TH REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2023.05.29
17:07:40 +05'30'

Dr. S. Surendranath Reddy

Bub r q s b e foj k

AF Tz - - 5266

M b7E vabo a
A q7/6J v)/- / 0

Standalone Statement of Cash flows		(Rs. in Lakhs except as stated)	
Sl. No.	Particulars	Year ended	Year ended
		31 March 2023	31 March 2022
		(Audited)	(Audited)
A	Cash flow from operating activities		
	Profit before tax	11,127.30	14,438.08
	Adjustments for:		
	Abnub f qf k ka j l ofp qf k bnr bkp	06 10	27 . 0 32
	bqd fkl k p ih obqobj bkq l enol nboq)mi kq ka bnr fnj bkq	% 3 -	% - 1 /
	Ikqobopqf k l j b	% 26 4 -	% 66 - / 1
	Obkq iRk l j b ad j fks bpj bkq Ml nboq	% 03 - -	% - -
	Ml ofq l k p ib l e j r q i ar ka fks bpj bkq % kbq	% 3 1 6	% 4 3 /
	T ofp l ad e il k p d fs bk	6 0 1	- - -
	Ml s fpl k ad oal r q r i ob b fs ibp	- - -	- - -
	Ml s fpl k ad oal r q r i as k bp	- - -	0 30
	Bnr fqr pbqj ba pe ob pba m vj bkq q k p % BPLM	4 . 34	. 0 23
	C fos ir b ad fkl k e f k f i p p b q j b p r o b a q C S M	% 52 1 1	% 03 / 2
	Cfk k b l p p	% 1 - 0	% 4 - 23
	I f f i f q b p k l i l k d b o b n r f o b a i f o f p k h	% 3 4 -	% . 02
	T l d h f k d n f q i a g r p j b k q 7		
	Ab ob p h % k ob p b f k a p a b ob b fs ibp	30 21	% 60 22
	Ab ob p h % k ob p b f k f s b k q ofp	7 . 4 0 2	% 3 - / -
	Ab ob p h % k ob p b f k l q b o f k k f i p p b q	7 3 . 6 0	% 55 - 6
	% k ob p b f k l q b o p p b q	% . 4 / 3	% 231 . .
	Ik ob p b f k a p a b m v i b p	4 1 3 3 4	0 0 05
	Ik ob p b f k n o l s f p l k p k a l q b o i f f i f q b p	6 3 / 5	. 5 . 5
	% Ab ob p b , Ik ob p b f k l q b o f k k f i i f f i f q b p	% 5 / 0 0	2 . 2 23
	Cash generated from operations	18,871.02	19,459.40
	Ik l j b q u m fa) k b q	% 3 - 4 1 2	% 6 . 4 / 3
	Net cash inflow from operating activities	16,263.57	15,542.14
B	Cash flows from investing activities		
	nr f p q l k l e n o l n b o q) m i k q k a b n r f n j b k q n f q i t l e h f k n o l d o b p p	% / % 1 2 2 5	% / % - 6 6 0
	% T I M) l q b o f k q k d f i b p p b q k a f k q k d f i b p p b q r k a b o a b s b i l n j b k q		
	% k i r a f k d n f q i a s k b p k a l n f q i o b a f q o p		
	Ml b b a p a d j i p i b l e n o l n b o q) m i k q k a b n r f n j b k q	/ 2 4 .	. 1 . 06
	Iks bpj bkq k i f n r fa j r q i ar ka p l ka p) k b q	% 5 - 0 5 1	% % 43 6 1
	Abn l p f q o b a b b j b a e s f k d l o f d f k i j q o f q l e j l o b a p k 0 j l k a p) k b q	5) 42 / 56	.) 10 6 1
	% Iks bpj bkq, o b a b j n f l k l e j o d f k j l k b v a b n l p f q) k b q		% - .
	I l k p d fs b k q i p r p f a f o b p		% / 2 - -
	I l k p o b m fa i v p r p f a f o b p	6 2 3 0	. 2 - - -
	Obkq iRk l j b ad j fks bpj bkq Ml nboq	0 3 - -	6 - -
	Ikqobopqob b fs ba	3 6 . 1 5	.) - 3 4 5
	Net cash outflow from investing activities	(10,847.71)	(12,662.77)
C	Cash flows from financing activities		
	M v j b k q l e i b p b i f f i f q b p	% 0 / . . 4	% % 4 . 3 4
	Ml b b a p a d j i b n r f q v p e o b p r k a b o B P L M p	. . 2 6 -	
	A s fa b k a p m fa	%) / - 3 1	
	Net cash outflow from financing activities	(4,125.91)	(2,471.67)
	Net increase in cash and cash equivalents (A + B + C)	1,289.95	407.70
	pe ka pe bnr fs ibkq q q b b d f k k f k d l e q b n b o l a	.) 0 6 - /	3 0 . 0 /
	Cash and cash equivalents at end of the period	2,328.97	1,039.02
	pe ka pe bnr fs ibkq p n b o l s b l j m f p b l e q b d i l t f k d 7		
		As At	As At
		March 31, 2023	March 31, 2022
	pe l k e ka	21 2 -	20 2 5
	i k b p i f q k h p		
	f k r o o b k q l r k q) 4 / 2 -	6 5 2 1 1
	r k m fa a f s fa b k a l r k q	1 4	
	f k a b n l p f q l r k q p e s f k d j q o f q i b p p a k a o b b j l k a p p	% - . 2 -	
	Total cash and cash equivalents	2,328.97	1,039.02

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANATH
H REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2023.05.29
17:07:56 +05'30'

Dr. S. Surendranath Reddy

Bub r q s b e f o j k
AF 7 - - - 5266

M b 7 E v a b o a
A q 7 / 6 J v j l - / 0

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City, Orwell, B Wing,
6th Floor, Unit-3, Sy No. 83/1, Plot No. 02,
Raidurg, Hyderabad – 500 081 – India
Tel: +91 407 182 2000
Fax: +91 407 182 2399

Independent Auditor's Report

To the Board of Directors of Vijaya Diagnostic Centre Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2023, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate/ consolidated audited financial statements of the subsidiaries, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the following entities
 1. Vijaya Diagnostic Centre Limited (**Parent**)

Subsidiaries

2. Medinova Diagnostic Services Limited
 3. VDC Diagnostics (Karnataka) LLP
 4. Doctors Lab Medical Services Private Limited
 5. Medinova Millenium MRI Services LLP
 6. Namrata Diagnostic Centre Private Limited
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our

Registered Office:

B S R & Associates (a partnership firm with Registration No. BA69226) converted into B S R & Associates LLP (a Limited Liability Partnership with LLP Registration No. AAB-8182) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited

other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in sub paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company/ LLP and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies / Designated Partners of limited liability partnerships (LLP) included in the Group are responsible for assessing the ability of each company / LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/designated partners either intends to liquidate the company / LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies / Designated Partners of the LLP included in the Group is responsible for overseeing the financial reporting process of each company / LLP.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited

in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

- a. The consolidated annual financial results include the audited financial results of five subsidiaries, whose financial statements reflect total assets (before consolidation adjustments) of Rs. 1,312.02 lakhs as at 31 March 2023, total revenue (before consolidation adjustments) of Rs. 1,002.30 lakhs and total net profit after tax (before consolidation adjustments) of Rs. 197.31 lakhs and net cash inflows (before consolidation adjustments) of Rs 22.73 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The independent auditor's report on financial statements of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

- b. The consolidated annual financial results include the results for the quarter ended 31 March 2023

Independent Auditor's Report (Continued)

Vijaya Diagnostic Centre Limited

being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Associates LLP**

Chartered Accountants

Firm's Registration No.:116231W/W-100024

AMIT
KUMAR
BAJAJ

Digitally signed
by AMIT KUMAR
BAJAJ
Date: 2023.05.29
17:33:07 +05'30'

Amit Kumar Bajaj

Partner

Hyderabad

29 May 2023

Membership No.: 218685

UDIN:23218685BGXHIT1670



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March 2023

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended	
		31 March 2023	31 December 2022	31 March 2022	31 March 2023	31 March 2022
		Audited (Refer Note 4)	Unaudited	Audited (Refer Note 4)	Audited	Audited
1	Income					
	(a) Revenue from operations	12,099.28	11,311.85	11,620.03	45,922.27	46,236.99
	(b) Other income	451.89	355.82	319.09	1,415.07	1,283.06
	Total income	12,551.17	11,667.67	11,939.12	47,337.34	47,520.05
2	Expenses					
	(a) Cost of materials consumed	1,553.00	1,366.53	1,787.76	5,888.16	7,149.91
	(b) Employee benefits expense	1,952.64	1,973.32	1,919.74	7,847.74	7,065.94
	(c) Finance costs	576.86	554.03	433.51	2,094.79	1,645.03
	(d) Depreciation and amortisation expense (Refer Note 5)	1,135.62	2,028.49	1,528.06	6,172.01	5,268.61
	(e) Other expenses	3,682.96	3,543.44	3,126.88	13,983.64	11,652.13
	Total expenses	8,901.08	9,465.81	8,795.95	35,986.34	32,781.62
3	Profit before tax [1 - 2]	3,650.09	2,201.86	3,143.17	11,351.00	14,738.43
4	Tax expense					
	(a) Current tax	795.62	587.02	830.83	2,776.18	3,954.73
	(b) Deferred tax, net	81.80	(30.77)	(76.02)	54.12	(283.06)
	Total tax expense	877.42	556.25	754.81	2,830.30	3,671.67
5	Profit for the period/year [3-4]	2,772.67	1,645.61	2,388.36	8,520.70	11,066.76
6	Other comprehensive income					
	<i>Items that will not be reclassified to profit or loss</i>					
	(a) Remeasurement of the defined benefit obligations	7.79	6.39	35.93	26.94	27.62
	(b) Income-tax relating to above item	(1.96)	(1.61)	(8.88)	(6.78)	(6.96)
	Other comprehensive income for the period/year (net of tax)	5.83	4.78	27.05	20.16	20.66
7	Total comprehensive income for the period/year [5+6]	2,778.50	1,650.39	2,415.41	8,540.86	11,087.42
	Profit for the period attributable to:					
	Owners of the Company	2,749.28	1,636.36	2,371.25	8,463.16	10,968.06
	Non controlling interests	23.39	9.25	17.11	57.54	98.70
	Other comprehensive income attributable to:					
	Owners of the Company	5.54	4.78	26.21	19.87	20.07
	Non controlling interests	0.29	-	0.84	0.29	0.59
	Total comprehensive income attributable to:					
	Owners of the Company	2,754.82	1,641.14	2,397.46	8,483.03	10,988.13
	Non controlling interests	23.68	9.25	17.95	57.83	99.29
8	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6)	1,020.71	1,020.69	1,019.66	1,020.71	1,019.66
9	Other equity				53,452.23	45,802.27
10	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 6)					
	- Basic (in Rs.)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)
	- Diluted (in Rs.)	2.69	1.60	2.33	8.29	10.76
		2.68	1.60	2.31	8.26	10.69

Notes:

- The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.
- The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 29 May 2023. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion on these results.
- The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- The consolidated figures for the quarter ended 31 March 2023 and 31 March 2022 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the date of third quarter of the respective financial years.
- The Group has charged depreciation on Property, Plant and Equipment based on Written Down Value ("WDV") method from 01 April 2022 to 31 December 2022. With effect from 01 January 2023, the Group has changed its method of depreciation from WDV to SLM (Straight Line Method) based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Accordingly, the depreciation expense is lower and profit before tax is higher by Rs. 904.34 lakhs for the quarter and year ended 31 March 2023. There is no impact on account of such change to the depreciation provided in the results for the quarter and nine months period ended 31 December 2022.
- During the quarter and year ended 31 March 2023, the Company has issued 1,913 and 105,249 equity shares of face value of Rs. 1 each on exercise of employee stock options.
- The Board of Directors at its meeting held on 29 May 2023, has proposed and recommended a dividend of Re. 1/- per equity share of Re. 1/- each i.e., 100% for the financial year 2022-23, subject to the approval of the members at the ensuing annual general meeting.
- The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com
- Corresponding previous period figures have been regrouped / reclassified wherever necessary.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRAN
ATH REDDY

Dr. S. Surendranath Reddy
Executive Chairman
DIN: 00108599

Digitally signed by
SURA SURENDRANATH
REDDY
Date: 2023.05.29
17:05:59 +05'30'

Place: Hyderabad
Date: 29 May, 2023

Consolidated Statement of Cash flows		(Rs. in Lakhs except as stated)	
Sl.No	Particulars	Year ended 31 March 2023	Year ended 31 March 2022
		Audited	Audited
A.	Cash flow from operating activities		
	Profit before tax	11,351.00	14,738.43
	<i>Adjustments for:</i>		
	Depreciation and amortisation expense	6,172.01	5,268.61
	Net gain on sale/ retirement of property, plant and equipment	(8.60)	(39.79)
	Interest income	(828.00)	(979.86)
	Profit on sale of mutual fund investments, (net)	(86.49)	(47.62)
	Provision for doubtful receivables	23.28	-
	Provision for doubtful advances	20.00	43.63
	Fair value movement on financial instruments	(385.44)	(136.25)
	Liabilities no longer required, written back	(90.00)	(21.35)
	Equity-settled share based payment transactions	71.67	113.56
	Finance costs	1,942.46	1,521.49
	Working capital adjustments:		
	Decrease / (Increase) in inventories	222.82	(163.24)
	Decrease / (Increase) in trade receivables	4.94	(306.64)
	Decrease / (Increase) in other financial assets	261.82	(287.92)
	(Increase) in other assets	(205.03)	(551.05)
	Increase / (Decrease) in trade payables	697.60	(30.97)
	(Decrease) / Increase in provisions and other liabilities	101.52	174.90
	(Decrease) / Increase in other financial liabilities	(182.07)	496.35
	Cash generated from operations	19,083.49	19,792.28
	Income tax paid, net	(2,622.32)	(3,992.41)
	Net cash inflow from operating activities	16,461.17	15,799.87
B.	Cash flows from investing activities		
	Acquisition of property, plant and equipment, capital work-in-progress (CWIP), other Intangible assets and intangible assets under development (including capital advances and capital creditors)	(12,484.26)	(12,234.85)
	Proceeds from sale of property, plant and equipment	25.42	142.03
	Investment in debt oriented liquid mutual funds/bonds, (net)	(8,003.84)	(2,476.94)
	Deposits redeemed having original maturity of more than 3 months, (net)	8,868.52	1,207.81
	Purchase of further stake from NCI in subsidiary	-	(170.00)
	Interest received	636.92	1,225.72
	Net cash outflow from investing activities	(10,957.24)	(12,306.23)
C.	Cash flows from financing activities		
	Repayment of long-term borrowings	-	(327.45)
	(Repayments) to short-term borrowings, net	(63.46)	(56.23)
	Proceeds from the exercise of employee stock option	115.90	-
	Dividend paid on equity shares	(1,021.11)	-
	Payment of lease liabilities	(3,221.17)	(2,471.67)
	Interest paid	(1.39)	(201.86)
	Net cash outflow from financing activities	(4,191.23)	(3,057.21)
	Net increase in cash and cash equivalents (A + B + C)	1,312.70	436.43
	Cash and cash equivalents at the beginning of the year	1,104.99	668.56
	Cash and cash equivalents at end of the year	2,417.69	1,104.99

Cash and cash equivalents as per above comprise of the following:

	March 31, 2023	March 31, 2022
Cash on hand	56.05	54.93
Balances with banks		
- in current accounts	1,159.67	1,035.80
- unpaid dividend accounts	0.47	-
- in deposit accounts having maturity less than three months	1,201.50	14.26
Total cash and cash equivalents	2,417.69	1,104.99

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SURA
SURENDRANA
TH REDDY

Digitally signed by SURA
SURENDRANATH REDDY
Date: 2023.05.29
17:06:40 +05'30'

Dr. S. Surendranath Reddy
Executive Chairman
DIN: 00108599

Place: Hyderabad
Date: 29 May, 2023